AB103: Clinical Trials

2 trials of AB103, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 terminated. 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 32Completed 1, Terminated 1

Follow AB103: new trials by email Literature Review of AB103 trials Research Report on AB103

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase 3 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury
Reltecimod 0.5 mg/kg, Placebo - Acute Kidney Injury, Peritonitis
Phase 3TerminatedAtox Bio Ltd582018-05-242021-10-12
Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections
AB103 0.5 mg/kg, NaCl 0.9% - Necrotizing Soft Tissue Infections, Necrotizing Fasciitis
Phase 3CompletedAtox Bio Ltd2902015-12-012021-10-05

Conditions studied

Acute Kidney Injury (1)  ·  Fasciitis, Necrotizing (1)  ·  Fournier Gangrene (1)  ·  Intraabdominal Infections (1)  ·  Peritonitis (1)

Sponsors

Atox Bio Ltd (2)

Countries

France (2)  ·  United States (2)

Top investigators

Azra Bihorac, MD (1)  ·  Eileen M Bulger, MD (1)  ·  Wayne M Dankner, MD (1)

Results publications

PMID 32657946